Scarica l'app Stockscreener
24.68
3.12%
-0.795
Dopo l'orario di chiusura:
24.69
0.005
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$25.48
Aprire:
$25.56
Volume 24 ore:
408.97K
Relative Volume:
1.04
Capitalizzazione di mercato:
$748.69M
Reddito:
$339.92M
Utile/perdita netta:
$-12.83M
Rapporto P/E:
-57.47
EPS:
-0.4295
Flusso di cassa netto:
$4.52M
1 W Prestazione:
+2.17%
1M Prestazione:
+11.60%
6M Prestazione:
-41.56%
1 anno Prestazione:
+50.24%
Intervallo 1D:
$24.35
$25.62
Intervallo di 1 settimana:
$23.25
$25.62
Portata 52W:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
24.68 | 748.69M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CSTL|Castle Biosciences Inc|Price:24.700|Chg%:-0.780 - TradingKey
Castle Biosciences sets live webcast for Aug. 12 conference - Stock Titan
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test - The Dermatology Digest
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Castle Biosciences CEO Maetzold sells $95,622 in company stock - Investing.com UK
Form 4 Castle Biosciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com - Investing.com UK
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts - Stock Titan
Castle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606 - Bitget
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test - marketscreener.com
Castle Biosciences receives New York approval for atopic dermatitis test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - norfolkneradio.com
CSTL Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Uncertain Revenue Outlook - DonanımHaber
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
CSTL Q1 2026 Earnings: Slight EPS Beat Amid Operational ProgressRevenue Guidance Update - DonanımHaber
July 30 set for Castle Biosciences Q2 2026 earnings webcast - Traders Union
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - Yahoo Finance
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - Ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com India
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsDynamic Hedging - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
CSTL Initiated by Roth Capital -- Price Target Announced at $40. - GuruFocus
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.02%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):